XML 32 R22.htm IDEA: XBRL DOCUMENT
v3.19.2

Major Customers, Partnerships and Strategic Alliances (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2019
Kite Pharma Inc |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three and six months ended June 30, 2019 and 2018 were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Revenue related to Kite agreement: |  |  |  |  |  |  |
Recognition of upfront fee | $ | 6,227 |  |  | $ | 5,953 |  |  | $ | 12,386 |  |  | $ | 5,953 |
Research services | 2,833 |  |  | 1,562 |  |  | 4,986 |  |  | 1,562 |
Total | $ | 9,060 |  |  | $ | 7,515 |  |  | $ | 17,372 |  |  | $ | 7,515 |
Pfizer SB-525 |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three and six months ended June 30, 2019 and 2018 were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Recognition of upfront fee related to Pfizer SB-525 agreement | $ | 4,635 |  |  | $ | 8,183 |  |  | $ | 1,595 |  |  | $ | 15,841 |
Pfizer |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three and six months ended June 30, 2019 and 2018 were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Recognition of upfront fee related to Pfizer C9ORF72 agreement | $ | 455 |  |  | $ | 617 |  |  | $ | 1,070 |  |  | $ | 1,076 |
Bioverativ Inc |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three and six months ended June 30, 2019 and 2018 were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Revenue related to Sanofi agreement: |  |  |  |  |  |  |
Recognition of upfront fee | $ | 901 |  |  | $ | 1,184 |  |  | $ | 1,654 |  |  | $ | 2,338 |
Research services | 2,158 |  |  | 3,332 |  |  | 3,355 |  |  | 6,560 |
Total | $ | 3,059 |  |  | $ | 4,516 |  |  | $ | 5,009 |  |  | $ | 8,898 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |